Recombinant Human Siglec-3 (C-mFc)

Description

EnkiLife provides the Recombinant Human Siglec-3 (C-mFc) protein,aslo know as Myeloid Cell Surface Antigen CD33,Sialic Acid-Binding Ig-Like Lectin 3,Siglec-3,gp67,CD33,SIGLEC3, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Myeloid cell surface antigen CD33 is produced by our Mammalian expression system and the target gene encoding Asp18-His259 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:AAH28152.1. Expression Host:Human cells.Species:Human.Predicted Molecular Mass:53.5 kDa. Background:CD33 is a type I Lectin belonging to the Ig superfamily. CD33 contains an N terminal Ig like V type domain, which mediates sialic acid binding, followed by one Ig like C2 type domain, a transmembrane region and a cytoplasmic tail containing two conserved immunoreceptor tyrosine based inhibition motifs (ITIMs). Eleven human Siglecs have been characterized. Siglecs 5 to 11 share a high degree of sequence similarity with CD33/Siglec3 both in their extracellular and intracellular regions. They are collectively referred to as CD33 related Siglecs. CD33 related Siglecs have differential expression pattern within the hematopoietic system. They are involved in the regulation of cellular activation within the immune system. Siglec 3 expression is restricted to cells of myelomonocytic lineage. Siglec3 recruits SHP1 and SHP2 to its ITIMs upon phosphorylation.